Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-20
2006-06-20
Hui, San-Ming (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07064145
ABSTRACT:
Methods for preventing beta cell degeneration, such as necrosis or apoptosis of beta cells in a subject, comprising administering a DPP-IV inhibitor to a subject in need thereof. The invention furthermore relates to a method for increasing the number and/or the size of beta cells. The invention also relates to a method for delaying the progression of Impaired Glucose Tolerance (IGT) to type 2 diabetes, as well as a method for delaying the progression of non-insulin demanding type 2 diabetes to insulin-demanding type 2 diabetes.
REFERENCES:
patent: 5585347 (1996-12-01), Meier et al.
patent: WO 98/19998 (1998-05-01), None
Shafrir et al., Annals New York Academy of Sciences, Nov. 18, 1999;892:223-46.
Holst et al., Diabetes, vol. 47, pp. 1663-1670 (1998).
Bork Richard W.
Green Reza
Hui San-Ming
Novo Nordisk A S
Wilk-Orescan Rosemarie R.
LandOfFree
Inhibition of beta cell degeneration does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of beta cell degeneration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of beta cell degeneration will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3676579